Europe Renews Innovative Medicines Initiative, With Funding Boost
This article was originally published in The Pink Sheet Daily
Executive Summary
With a new budget of €3.4 billion over the next seven years, Europe’s public-private partnership in health aims to tackle difficult-to-treat neurodegenerative diseases and new antibiotics.
You may also be interested in...
EU ADR App To Underpin Region’s Regulatory Approach To Social Media
EU regulators are set to launch an adverse drug reaction reporting app in March and will follow this up with a social media monitoring drive to improve pharmacovigilance.
On Visit To Japan, Sanofi’s Viehbacher Weighs In On Innovation Models, Clinical Trial Transparency
Increased funding and public-private interaction in a new research “control tower” would be welcomed by industry in Japan, Viehbacher said. But the CEO told PharmAsia News that he opposes expanded regulatory oversight on clinical trial transparency.
In Europe, A Public-Private Effort Could Shed Light On The Tricky Business Of Cancer Vaccines
With EU cash in hand, the GAPVAC consortium aims to develop tailor-made vaccines for patients with the rare but aggressive brain cancer, glioblastoma. The vaccines will be unique to each individual, but hopefully with increased efficacy compared with other therapies, thereby justifying the likely higher cost and complexity of treatment.